{"id":403901,"date":"2026-03-25T23:09:12","date_gmt":"2026-03-25T23:09:12","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/403901\/"},"modified":"2026-03-25T23:09:12","modified_gmt":"2026-03-25T23:09:12","slug":"fda-approves-new-wegovy-hd-with-triple-the-dosage-of-the-semaglutide-medication","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/403901\/","title":{"rendered":"FDA approves new ‘Wegovy HD’ with triple the dosage of the semaglutide medication"},"content":{"rendered":"

The US Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection.<\/a><\/p>\n

The 7.2 mg dosage, called Wegovy HD, is intended for\u00a0weight loss\u00a0and long-term weight loss maintenance<\/a> for adult patients. It is triple the previous maximum dose of 2.4 mg.<\/p>\n

This marks the fourth approval in the FDA\u2019s National Priority Voucher pilot program, which \u201cseeks to expedite approval of applications that address critical national health priorities,\u201d according to FDA Commissioner Dr. Martin Makary.<\/p>\n

\u201cThe new FDA is moving with unprecedented efficiency on products that advance national priorities,\u201d he said in a press release. \u201cToday\u2019s approval is another demonstration of what the FDA can accomplish when we try bold new things.\u201d<\/p>\n

The higher-dose GLP-1 is indicated to \u201creduce excess body weight and maintain weight reduction long-term in\u00a0adults with obesity, or overweight with at least one weight-related condition,\u201d per the FDA\u2019s statement.<\/p>\n

\u201cThe approval of a new higher dose will provide adult patients with an additional therapeutic option, offering the potential for greater weight loss,\u201d the agency stated.<\/p>\n

The FDA\u2019s approval, granted to drugmaker Novo Nordisk, was supported by clinical data that found higher doses resulted in additional average weight reduction compared to previous dosing.\u00a0<\/p>\n

Higher-dose patients with both obesity and\u00a0type 2 diabetes\u00a0saw similar lowering of blood sugar compared to the lower dose, the agency noted.<\/p>\n

\"WegovyThe FDA announced that it has approved a new higher-dose injection from Wegovy. Road Red Runner \u2013 stock.adobe.com<\/p>\n

The safety profile is consistent with the known side effects of semaglutide<\/a>, which commonly include\u00a0gastrointestinal reactions\u00a0like nausea, vomiting, diarrhea, constipation and abdominal pain.<\/p>\n

Skin sensitivity, pain or burning occurred more frequently with higher doses of Wegovy, but generally resolved on their own or with dose reduction, the FDA reported. <\/p>\n

The agency is investigating these adverse effects.<\/p>\n

The FDA warned that Wegovy should not be used by patients with a personal or family history of medullary thyroid carcinoma (a type of\u00a0thyroid cancer) or who have multiple endocrine neoplasia syndrome type 2 (a rare inherited genetic disorder that causes tumors to develop in certain hormone-producing glands). <\/p>\n

All patients should see a doctor for guidance on proper use.<\/p>\n

Jamey Millar, executive vice president of US operations for Novo Nordisk, commented on this approval in a press release.<\/p>\n

\u201cWe are excited to bring Wegovy HD injection to adults with obesity who are looking for powerful weight loss, as no other weight-loss medicine has been studied to show superiority to Wegovy HD,\u201d he said.\u00a0<\/p>\n

Millar also noted that Wegovy has been shown to reduce the risk of events such as stroke, heart attack or cardiovascular death in those who also have known heart disease.<\/p>\n

Dr.\u00a0Peter\u00a0Balazs, a hormone and weight-loss specialist practicing in New York and New Jersey, reflected on results of the STEP UP clinical trial, on which the drug\u2019s approval was based.<\/p>\n

Patients taking the higher dose experienced an average weight loss of 20.7% compared to about 16% on the standard dose, the doctor noted. <\/p>\n

About one-third lost 25% or more of their body weight.<\/p>\n

\u201cFor patients who start on 2.4 mg and then hit a frustrating plateau, or for those with a very high baseline BMI who may need a stronger metabolic push, this creates a legitimate, evidence-based escalation path rather than forcing an early switch to another drug class,\u201d Balazs, who was not involved in the study, told Fox News Digital.<\/p>\n

\t\t\t\t\t\t\tStart your day with all you need to know\t\t\t\t\t\t<\/p>\n

\n\t\t\t\t\t\t\tMorning Report delivers the latest news, videos, photos and more.\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\tThanks for signing up!\n\t\t\t\t<\/p>\n

\u201cThat said, I think this is an interesting approval, but I do not expect it to dramatically reshape the GLP-1 landscape,\u201d he went on. \u201cIt gives Novo Nordisk an opportunity to remain competitive on efficacy while it continues developing\u00a0next-generation therapies.\u201d<\/p>\n

\u201cOther drugs have already shown greater efficacy in prior studies, and the broader GLP-1 space is likely to see much more significant change as new molecules enter the market.\u201d<\/p>\n

Balazs called the higher dosage a \u201cmajor jump,\u201d noting that the incidences of stomach- and\u00a0skin-related\u00a0side effects at this higher dose are \u201cmeaningful.\u201d<\/p>\n

\u201cThis approval is for obesity management, not\u00a0diabetes treatment,\u201d the expert emphasized. \u201cFor patients with type 2 diabetes, currently approved semaglutide dosing remains lower unless the primary treatment goal is weight loss under the obesity indication.\u201d<\/p>\n

Fox News Digital reached out to the FDA for comment.<\/p>\n","protected":false},"excerpt":{"rendered":"The US Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection.…\n","protected":false},"author":2,"featured_media":403902,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[274],"tags":[18,2898,1950,135,19,17,462,2900,564,2555],"class_list":{"0":"post-403901","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-eire","9":"tag-fda","10":"tag-glp-1","11":"tag-health","12":"tag-ie","13":"tag-ireland","14":"tag-medication","15":"tag-pharmaceuticals","16":"tag-weight-loss","17":"tag-wellness"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116292338591028609","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/403901","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=403901"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/403901\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/403902"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=403901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=403901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=403901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}